Phase 3 Pancreatic Cancer Trial, Recruiting NCT06881992 Sponsor: Rezolute Condition: Pancreatic Cancer
Back to Pancreatic Cancer

Phase 3 Pancreatic Cancer Trial, Recruiting

NCT06881992
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 or older who are willing to give written consent to participate.
  • People who have been clinically diagnosed with a neuroendocrine tumor (a type of tumor that can affect hormone production) that is causing the body to produce too much insulin, leading to dangerously low blood sugar levels, confirmed through lab tests.
  • People whose low blood sugar has not been adequately controlled despite standard treatments, as determined by the treating doctor.
  • People who have been receiving glucose through a drip (IV) or through nutritional support delivered directly into the bloodstream for at least 7 days before starting the trial, to manage their low blood sugar.
  • Eligibility for all participants must be reviewed and confirmed by a specialist medical team, including an oncologist (cancer specialist), led by the principal investigator.

Who may not be able to join:

  • People who have an active infection, including HIV, hepatitis B, or hepatitis C (not related to vaccination history).
  • People who have taken part in another clinical drug or device trial within the past 30 days, or within 5 half-lives of that investigational drug — whichever is the longer period (though exceptions may be considered by the medical team in certain circumstances; participation in registries or purely diagnostic studies is allowed).
  • People whose blood test results at the screening stage (other than blood sugar levels) show values outside the normal range that the investigator considers clinically significant (some exceptions may be allowed if the abnormality is related to the tumor or its treatment and does not pose additional risk).
  • People who are known to have an allergy or sensitivity to ersodetug (the study drug) or any of its ingredients.
  • People who have another serious health condition — such as a significant psychiatric illness, severe alcohol or drug dependence, or serious heart, liver, or kidney disease — that the investigator or medical monitor believes would make participation unsafe.
  • People whose underlying disease is estimated to give them a remaining life expectancy of less than 8 weeks.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 650-206-4507

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Rezolute
Registry
ClinicalTrials.gov
Start date
16 April 2025
Est. completion
1 September 2027

Where this trial is recruiting

🇫🇷 France 🇳🇱 Netherlands 🇨🇭 Switzerland 🇬🇧 United Kingdom 🇺🇸 United States

Primary endpoints

Proportion of participants with clinically meaningful reduction in IV glucose infusion rate from baseline.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov